MNTA: I haven't any idea how MNTA will trade this week, but I'd be mildly surprised to not see a $30 print. (Especially since the news came out of left field mid-day on a Friday).I have no intention of parting with my shares.
There will be substantial analyst commentary, however, most do not have any idea of how to model Lovenox revenues for MNTA. MNTA cannot give any guidance to them at this point, thus, price targets will likely be all over the map. (But all should be positive!)
A bigger issue for me is how they now model possible generic Copaxone revenues. The probable outcome for Copaxone is now less in doubt from a regulatory standpoint; however, the litigation angle takes on greater importance, imo. Nonetheless, analysts must now pay deference to possible Copaxone sales under favorable terms for MNTA in a $2B market.
Market Data 
Markets 
AI
